Selenocysteine insertion sequence binding protein 2 (SBP2) is an essential factor in selenoprotein synthesis. Patients with SBP2 defects have a characteristic thyroid phenotype and additional manifestations such as growth delay, male infertility, impaired motor coordination, and developmental delay. The thyroid phenotype has become pathognomonic for this defect, and putative deficiencies in the iodothyronine deiodinases selenoenzymes have been implicated. To investigate the role of SBP2 and selenoproteins in thyroid physiology and answer questions raised by the human syndrome, we generated a tamoxifen-inducible Sbp2 conditional knockout (iCKO) mouse model. These Sbp2-deficient mice have high serum thyroxine (T4), thyrotropin, and reverse triiodothyronine (T3), similar to the human phenotype of SBP2 deficiency, whereas serum T3 is normal. Their liver T4 and T3 content reflect the serum levels, and deiodinase 1 expression and enzymatic activity were decreased. In contrast, brain T3 content is decreased, indicative of local hypothyroidism, confirmed by the decreased expression of the thyroid hormone (TH) positively regulated gene hairless. Interestingly, the cerebrum T4 content did not parallel the high serum T4 levels, and the expression of TH transporters was decreased. Deiodinase 2 enzymatic activity and deiodinase 3 expression were decreased in cerebrum. The expression and/or activity of other selenoproteins were decreased in brain, liver, and serum, thus demonstrating a global deficiency in selenoprotein synthesis. Sbp2 iCKO mice replicate the thyroid phenotype of SBP2 deficiency and represent an important tool to advance our understanding of the role of SBP2 in thyroid homeostasis and for investigating selenoprotein biology relevant to human disease. (Endocrinology 158: 4317-4330, 2017) S elenium (Se) is an essential micronutrient that supports important cellular functions. The biological effects of Se are predominately mediated through selenoproteins, which contain the rare amino acid selenocysteine (Sec) incorporated through recoding of a UGA stop codon. There are 25 genes encoding selenoproteins in humans. Although the functions of many selenoproteins are still unknown, some characterized mammalian selenoproteins were found to serve in antioxidant defense, oxidoreduction, thyroid hormone (TH) metabolism, and immune responses. Sec insertion sequence binding protein 2 (SBP2) is an essential factor required for Sec incorporation into selenoprotein molecules.
S elenium (Se) is an essential micronutrient that supports important cellular functions. The biological effects of Se are predominately mediated through selenoproteins, which contain the rare amino acid selenocysteine (Sec) incorporated through recoding of a UGA stop codon. There are 25 genes encoding selenoproteins in humans. Although the functions of many selenoproteins are still unknown, some characterized mammalian selenoproteins were found to serve in antioxidant defense, oxidoreduction, thyroid hormone (TH) metabolism, and immune responses. Sec insertion sequence binding protein 2 (SBP2) is an essential factor required for Sec incorporation into selenoprotein molecules.
Important medical clues to the consequences of impaired selenoprotein synthesis became apparent with our report of the first mutations in the SBP2 gene causing partial SBP2 deficiency (Online Mendelian Inheritance in Man 607693). Patients with SBP2 defects are homozygous or compound heterozygous for different SBP2 mutations causing partial SBP2 deficiency. Affected subjects manifest growth retardation associated with characteristic abnormal thyroid function tests (TFTs) (1), high serum total and free thyroxine (T4) concentrations, decreased serum 3,5,3 0 -triiodothyronine (T3), high 3,3 0 ,5 0 -T3 or reverse T3 (rT3), and normal or slightly elevated thyrotropin (TSH). This pattern of TFTs has not been identified in other inherited or acquired defects, and the exact mechanisms responsible for this consistent pattern remain elusive. Additional features are also reported, such as: congenital myopathy, developmental delay, impaired coordination, male infertility, sensorineural hearing loss, photosensitivity, immune deficits, and a metabolic phenotype (2) (3) (4) (5) , probably reflecting multiple selenoprotein deficiencies.
Many questions have been raised by the human phenotype of SBP2 deficiency. In vivo studies in a model organism are required to fully assess the pathophysiology responsible for the thyroid phenotype and other manifestations. The observed TFT pattern is indicative of defects in TH metabolism. Thus, it has been proposed that decreased activities of the deiodinases selenoenzymes would be responsible for the phenotype (6) . However, the exact mechanisms for the TFT abnormalities and how the interplay of the three deiodinase activities in different tissues contributes to the phenotype remain unknown. Previous hepatocyte and neuron-specific Sbp2-deficient mouse models (7, 8) have not been reported to manifest a thyroid phenotype, and constitutive Sbp2 knockout (KO) mice die during embryonic life (7) . Therefore, our goal was to generate a model with partial Sbp2 deficiency with global distribution to be induced later in life to bypass the embryonic lethality. To this end, we generated a tamoxifeninducible Sbp2 conditional KO (iCKO) mouse model.
The Sbp2 iCKO mice manifest a TFT pattern similar to those observed in SBP2-deficient patients: they have higher serum TSH, higher T4, similar T3, and higher rT3 compared with Wt mice. With the exception of serum T3 levels, which are low in SBP2-deficient patients, these TFTs in mice replicate the pathognomonic thyroid phenotype of SBP2 deficiency and thus confirm the utility of this mouse model for understanding the pathophysiology of the thyroid phenotype in SBP2 deficiency.
Materials and Methods

Generation of the Sbp2 iCKO mice
The targeting vector for the production of the Sbp2 iCKO mouse model was generated using recombineering techniques (https://redrecombineering.ncifcrf.gov/). The bacterial competent strains and plasmids needed for the recombineering protocol were made available by National Institutes of Health. The correct sequence of the targeting vectors was verified prior to electroporation into embryonic stem (ES) cells by restriction enzyme digestion and sequencing. The bacterial artificial chromosome (BAC) clone used for engineering the targeting constructs was RP23-15P20 from mouse C57BL6/6J strain. The ES cells used for targeting were also derived from the same strain to contain isogenic genomic DNA (gDNA) as the BAC clone.
A ;9.2-kb gDNA fragment containing the 3 0 end of the Sbp2 gene was retrieved from the BAC clone for the targeting construct. The 5 0 and 3 0 homology arms were both ;4.6 kb (Fig. 1A) . In a first targeting step, the LoxP flanked NeoR cassette LoxP-Pgk-em7-Neo-LoxP was inserted in intron 13 to introduce the 5 0 LoxP site of the floxed allele. Electroporation into SW106 bacterial strain of the recombineering protocol, containing an arabinose-inducible Cre recombinase, results in removal of this cassette, leaving behind the LoxP site. In a second targeting step, another NeoR cassette, Frt-Pgk-em7-Neo-Frt-LoxP, flanked by two Frt sites and one LoxP site, was inserted in intron 14 for the 3 0 LoxP site of the floxed allele. This selection cassette was used for positive selection in ES cells. A total of 50 mg targeting vector linearized using the NotI unique restriction enzyme was electroporated into ES cells. NeoR cassette and TK cassette were used for positive and negative selection, respectively. Eleven out of 192 ES cell clones were positive for the correct targeting at both 5 0 and 3 0 ends by polymerase chain reaction (PCR) screening and confirmed by Southern blot. Targeted ES cells colonies were injected by workers at the University of Chicago Transgenic Mouse and Embryonic Stem Cell Facility into blastocysts, and male chimeras were generated. Once transmission of the targeted conditional allele (Fig. 1B) was confirmed in F1 mice, the allele having exon 14 flanked by LoxP sites (floxed allele) was obtained by removing the NeoR cassette by recombining the two Frt sites through breeding with mice ubiquitously expressing Flpe (009086; The Jackson Laboratory, Bar Harbor, ME). The constitutive KO Sbp2 allele (null) with exon 14 deleted was generated by breeding the transmitting male chimeras with mice ubiquitously expressing Cre recombinase (003755; The Jackson Laboratory). The generation of the homozygous null mice was attempted by breeding heterozygous null mice; however, as expected, they died in utero.
Tamoxifen is used to induce recombination of the LoxP sites in the floxed allele of mice compound heterozygous for the Sbp2 null and floxed alleles that are also heterozygous for a CreER transgene (008463; The Jackson Laboratory), resulting in the generation of the inducible Sbp2 conditional KO mice (Sbp2 iCKO). Several breeding steps are needed, as illustrated in Fig. 1C . In the first step, CreER heterozygous mice are bred with Sbp2 heterozygous null mice (Sbp2 Het KO in Fig. 1C ), resulting in 25% of progeny heterozygous for both the CreER transgene and the Sbp2 null allele. Mating these mice with Sbp2 homozygous floxed mice (Sbp2 floxed in Fig. 1C ) results in the generation of the inducible Sbp2 iCKO mice that are compound heterozygous for the Sbp2 null and floxed alleles and also heterozygous for the CreER transgene and represent 25% of the litter. The littermate controls identified as Wt for this study are heterozygous for the floxed allele at the Sbp2 locus but lack the CreER transgene and are also generated in the expected proportion of 25% (Fig. 1C) . The genotyping setup for the floxed and null alleles is shown in Fig. 1D using the following primers:
0 ; and P5, 5 0 -GCCTGGTAGTCACTAGATCCC-3 0 . For studies in this report, both male and female Sbp2 iCKO mice and Wt control animals were injected i.p. with 1 mg of tamoxifen for 4 consecutive days starting at postnatal days (P)28 to P35, during their fifth week of life. Body weights were measured before tamoxifen injection and then weekly for 4 weeks, before terminal bleeding and dissection. The studies were approved by The University of Chicago Institutional Animal Care and Use Committee.
Tissue collection processing and homogenization
Tissues were collected following blood removal by perfusion with heparinized phosphate-buffered saline through a needle placed in left heart ventricle. Tissues were immediately frozen on dry ice immediately and stored at 280°C. For further analysis, Extraction and measurement of tissue messenger RNA and gDNA Total RNA was extracted using phenol/guanidine isothiocyanate (Ribozol™ RNA extraction reagent; AMRESCO, Solon, OH), and 2 mg was reverse transcribed using SuperScript ® III First-Strand Synthesis System (Invitrogen, Waltham, MA) in the presence of 100 ng random hexamers. gDNA was extracted using a DNeasy Blood & Tissue Kit (Qiagen, Germantown, MD) according to the manufacturer's instructions. Reactions for the quantification of messenger RNAs (mRNAs) and gDNAs by real-time quantitative PCR (qPCR) were performed in an ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA) using SYBR Green I as detector dye. The oligonucleotide primers for mRNAs were designed to cross introns, except for iodothyronine deiodinase (Dio) 3, which is intronless. Primer sequences used for the qPCR of Sbp2; iodothyronine deiodinases (Dio1, Dio2, and Dio3); glycerol-3-phosphate dehydrogenase 2 (Gpd2); Spot14; uncoupling protein 2 (Ucp2); glucose-6-phosphatase (G6Pase); carnitine palmitoyltransferase 1A (Cpt1a); hairless (Hr); selenoprotein P1 (Sepp1), W1 (Sepw1), H (Selh), M (Selm), N1 (Sepn1), and T (Selt); Gpx1 and Gpx4; thioredoxin reductase (Txnrd) 1 (Txnrd1) and 3 (Txnrd3); selenophosphate synthetase 2 (Sps2); selenoprotein 15 (Sep15); monocarboxylate transporter (Mct) 8; organic anion transporters (Oatps) 1c1 (Oatp1c1), 3a1 (Oatp3a1), 1a1 (Oatp1a1), 1a4 (Oatp1a4), and 1b2 (Oatp1b2); L-type amino acid transporter (Lat) 1 and Lat2; and Na + -taurocholate cotransporting polypeptide (Ntcp) are provided in Table 1 . The housekeeping genes RNA polymerase II (RpII) and b-actin were used as internal controls for cerebrum and liver, respectively. Quantification of the Sbp2 gene deletion in gDNA was performed using primers amplifying part of intron 13 and exon 14, which is deleted in Sbp2 iCKO mice, normalized to a gDNA fragment amplifying part of intron 12 and exon 13 (Table 1) .
Western blotting
Protein samples were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and probed by immunoblotting Table 1 . Primer Sequences
AGGAGCCAGCTGGCACAGA CAGACCCGTGACACAAGCAT Sbp2 gDNA (intron 12 to exon 13) GCTGTGTCACTGGCACCAAG CTGGAACTCTGTGCCAGCTG Sbp2 gDNA (intron 13 to exon 14) TGGTGTCTTGGTGGCTTTTG TGGTACATGCGGTCTTGGAA with primary antibodies for Sbp2, Gpx1, Gpx3, b-actin, and albumin (Table 2) . Bound antibodies were detected by using horseradish peroxidase-conjugated secondary anti-rabbit or anti-goat antibodies (Table 2) and WesternBright ECL Spray (Advansta, Menlo Park, CA). The intensity of the band stain corresponding to the specified isoforms was quantified using the ImageJ software (National Institutes of Health). The values of arbitrary units assigned were normalized to those of b-actin for tissues and albumin for serum.
Measurement of serum TSH and iodothyronine concentrations and tissue T4 and T3 content
Measurements of TSH, total T4, T3, rT3 in serum, and T4 and T3 concentrations in tissue extracts were described in detail previously (9) .
Deiodinase enzymatic activity D1 and D2 enzymatic activities were measured as described previously (10, 11) . Results, expressed in picomoles (D1) and femtomoles (D2) of radioiodide generated per hour per milligram protein, were corrected for nonenzymatic deiodination in tissue-free controls.
Measurement of Gpx activity
Gpx activity was indirectly measured (12, 13) . Colorimetric assay for Gpx was performed according to the manufacturer's instructions (Bioxytech® cGPx-340 Assay; OXIS International, Inc., Beverly Hills, CA). Briefly, the sample to be analyzed was added to a solution containing glutathione, glutathione reductase, and nicotinamide adenine dinucleotide phosphate. The substrate tert-butylhydroperoxide was added, and absorbance at 340 nm was recorded. Observed values were normalized to protein content.
Protein measurement
Protein concentration of tissues was measured by the Bradford method using bovine serum albumin as the standard (14) . Values were used to express the tissue T4 and T3 content and D1, D2, and Gpx enzymatic activities and for western blot.
Statistical analysis
All results are expressed as mean 6 standard error of the mean. Statistical analysis of two groups was performed by Student t test. The P values of ,0.05 were considered to be significant.
Results
Generation of the Sbp2 iCKO mice
To bypass the early lethality of complete Sbp2 deficiency, a CreER/LoxP approach was used to generate Sbp2 iCKO mice. The C-terminus domain of SBP2 is highly conserved across species and is required for SECIS binding, ribosome binding, and Sec incorporation (15) . Specifically, exon 14, which encodes part of the C-terminus functional domains, was flanked for deletion by LoxP sites, and the resultant transcript between exons 13 and 15 is out of frame.
As detailed in the Materials and Methods section, two breeding steps were required to generate the Sbp2 iCKO and Wt mice littermates (Fig. 1C) . Genotypes born in these matings were in agreement with expected Mendelian ratios. The Sbp2 iCKO mice are compound heterozygous for the Sbp2 floxed and null alleles, and they are also heterozygous for the CreER transgene. In presence of tamoxifen, the expression of CreER results in the recombination of the LoxP sites flanking exon 14 in the floxed allele and deletes exon 14 in an inducible conditional manner. Sbp2 iCKO and Wt mice of both sexes received intraperitoneal injections of 1 mg tamoxifen for 4 days starting at P28 to P35, and mice were analyzed 4 weeks later. We observed that when injected at this time, Sbp2 iCKO mice survived for at least 10 months after tamoxifen injection. Tamoxifen injection starting at P25 results in severe failure to thrive and lethality by 3 weeks after tamoxifen injection in the majority of the Sbp2 iCKO mice. Both male and female Sbp2 iCKO mice are infertile in matings with unrelated Wt mice for .6 months. The efficiency of tamoxifen-induced Sbp2 gene deletion was examined at gDNA, mRNA, and protein levels. Real-time qPCR analysis using primers targeting the floxed region of Sbp2 revealed 70% and 65% reduction of the genomic amplicon in liver and cerebrum, respectively, in Sbp2 iCKO compared with Wt mice (Fig. 2A) . mRNA expression was also decreased by 79% and 67% in liver and cerebrum, respectively, in Sbp2 iCKO compared with Wt mice (Fig. 2B) . Western blot analysis revealed 67% and 74% reduction of the fulllength Sbp2 protein (molecular weight ;120,000) in liver (Fig. 2C) and cerebrum (Fig. 2D) , respectively, in Sbp2 iCKO compared with Wt mice. As the inducible mice are compound heterozygous (null/floxed) during development, the status of the Sbp2 protein isoforms prior to starting tamoxifen injection was investigated. Western blot of Sbp2 was performed on liver homogenates from the inducible mice and their Wt littermates at P21 (Supplemental Fig. 1 ). Although the long Sbp2 isoform was significantly decreased, and the lower isoforms were absent in the liver of tamoxifen-injected Sbp2 iCKO mice (Fig. 2C) , all Sbp2 isoforms are present in the liver of the uninjected Sbp2 inducible mice, at similar levels compared with Wt. This indicates minimal if any effect of the null/floxed genotype on Sbp2 protein levels prior to tamoxifen injection.
Decreased body weight of Sbp2 iCKO became notable in both males and females 2 weeks after starting tamoxifen injection, by 16% compared with Wt mice, and at 4 weeks postinjection was decreased by 24% in males and 26% in females (Fig. 3) . The decreased body weight was compatible with the failure-to-thrive phenotype observed in humans with SBP2 deficiency. Figure 2 . The efficiency of Sbp2 knockdown. Sbp2 (A) gDNA and (B) mRNA of liver and cerebrum. Five to eight male and female mice were studied in each group. As no differences were found between mice of same genotype irrespective of sex, results of both sexes were pooled per group. Western blot for Sbp2 and quantification in arbitrary units of the full-length Sbp2 isoform [molecular weight (MW) 120,000 indicated by arrows] normalized for b-actin in (C) liver and (D) cerebrum. For comparison of the Sbp2 isoforms present in these tissues, a Wt cerebrum sample is shown in (C), and a Wt liver sample is shown in (D), indicated in italics and separated by a dashed line. *P , 0.05; **P , 0.01; ***P , 0.001.
Serum TFTs in Sbp2 iCKO vs Wt mice
Serum TSH, T4, T3, and rT3 concentrations were measured in male and female mice 4 weeks after starting tamoxifen injection. Compared with Wt, male Sbp2 iCKO mice had 3.5-fold increase in TSH, 1.5-fold increase in T4 and comparable T3, and 2.3-fold increase in rT3 (Fig. 4A) . A similar pattern of TFT abnormalities was observed in the female Sbp2-deficient mice, though of slightly different magnitudes: 9.8-fold increase in TSH, 1.3-fold increase in T4 and comparable T3, and 1.4-fold increase in rT3 compared with Wt female mice (Fig. 4B) . Thus, with the exception of T3, the Sbp2 iCKO mice replicate the thyroid phenotype of human SBP2 deficiency.
We used the product of serum TSH and T4 levels, known as T4 resistance index (16) , to quantify the degree of pituitary resistance to TH in Sbp2 deficiency. Male Sbp2 iCKO mice had a product value of 555 vs 106 in Wt littermates, representing a 5.3-fold increase. Females Sbp2 iCKO had a T4 resistance index of 585 vs 47 in Wt controls, representing a 12.4-fold increase. These results indicate pituitary resistance to circulating TH levels in the setting of Sbp2 deficiency.
To assess efficiency of generating and maintaining circulating T3 levels in Sbp2 deficiency, the T3/T4 ratio was calculated. Male Sbp2 iCKO mice had a T3/T4 ratio of 9.8 vs 14.1 (ng/mg) in Wt littermates, representing a 0.7-fold decrease. Female Sbp2 iCKO had a T3/T4 ratio of 6.8 vs 9.6 in Wt controls, also representing a 0.7-fold decrease. These results indicate similarly decreased efficiency in generating circulating T3 in Sbp2 iCKO mice of both sexes. and (B) females. Twelve to 17 mice were studied in each group. *P , 0.05; **P , 0.01; ***P , 0.001.
Liver TH status in Sbp2 iCKO vs Wt mice
TH status and Dio1 mRNA and D1 enzymatic activity were measured in liver. Liver T4 content was increased in Sbp2 iCKO mice vs Wt controls by 1.4-fold in both males and females (Fig. 5A) , thus reflecting the increased serum T4 levels in Sbp2 deficiency. There was no considerable difference in liver T3 content between Sbp2 iCKO and Wt mice of both sexes (Fig. 5B) , also reflecting the similar serum T3 levels in both genotypes. However, the ratio of liver to serum T3 concentrations in individual mice was significantly decreased in Sbp2 iCKO compared with Wt mice (Fig. 5C) , suggesting a decrease of local T3 generation in Sbp2 iCKO mice. This is also supported by the decreased ratios of T3/T4 content by 0.6-and 0.7-fold, respectively, in male and female Sbp2 iCKO mice compared with the respective Wt littermates. The expression of several TH transporters was measured: Mct8, Mct10, Lat1, Lat2, Oatp1a1, Oatp1a4, Oatp1b2, Oatp3a1, and Ntcp (Supplemental Fig. 2 ). In males, Lat1 and Oatp1a1 had marked decrease (P , 0.05), whereas Oatp3a1 and Oatp1b2 had considerably increased expression (P , 0.05 and P , 0.01, respectively). The remaining transportersMct8, Mct10, Lat2, Oatp1a4, and Ntcp-had unaltered expression levels. In females, all transporters in the Sbp2 iCKO mice were expressed at similar levels as in the Wt. These data suggest that although changes in hepatic TH transport could contribute to the decreased ratio of hepatic T3 to serum T3 in male mice, this does not appear to be the case for female mice.
Reflecting the similar T3 content between genotypes, the expression of several TH responsive genes in liverGpd2, Spot14, Ucp2, G6pase, and Cpt1a-was similar between Sbp2 iCKO and Wt mice of both sexes (data not shown), indicating that overall TH action in liver is preserved in Sbp2 deficiency.
However, Dio1 mRNA expression was significantly decreased by 87% and 78% in male and female Sbp2 iCKO mice, respectively, compared with Wt mice (Fig. 5D ). D1 enzymatic activity was also significantly decreased by 69% and 51% in males and females, respectively (Fig. 5E) . The decreased liver Dio1 mRNA expression is primarily due to nonsense-mediated decay of the Dio1 mRNA in a setting of impaired UGA recoding due to Sbp2 deficiency.
Cerebrum TH status in Sbp2 iCKO vs Wt mice
TH status, Dio3 and Hr mRNA, and D2 enzymatic activity were measured in cerebrum. Sbp2 iCKO mice had a 29% and 35% decrease in cerebral T3 content in males and females, respectively, compared with Wt mice (Fig. 6A) . In terms of cerebral T4 content, although the levels were slightly elevated in Sbp2 iCKO mice, they were not noteworthy compared with Wt controls (Fig. 6B) . Reflecting the decreased T3 content, the mRNA expression of the TH-responsive gene Hr was significantly decreased in Sbp2 iCKO compared with Wt mice by 39% and 38% in males and females, respectively (Fig. 6C) . Dio3 mRNA expression was also significantly decreased in Sbp2 iCKO mice by 34% and 40% in males and females, respectively (Fig. 6D) . Of note, decreased Dio3 mRNA could be due to decreased TH action in a setting of decreased local T3, as Dio3 is a TH-responsive gene, and also due to impaired selenoprotein synthesis. Sbp2 iCKO mice had 47% and 52% decreased D2 enzymatic activity compared with Wt mice in males and females, respectively (Fig. 6E) . As cerebrum T4 content was comparable in both genotypes, the substratemediated posttranslational downregulation of Dio2 is less likely to contribute to the observed decreased D2 enzymatic activity, and thus, this is predominantly due to the impaired selenoprotein synthesis in Sbp2 defect. To investigate a possible mechanism responsible for the discrepant cerebrum TH content compared with serum, the expression of TH transmembrane transporters Mct8, Oatp1c1, Lat1, and Lat2 was measured. Compared with Wt littermates, male Sbp2 iCKO had 39% and 47% decreased expression of Mct8 and Oatp1c1, respectively, whereas female Sbp2 iCKO had 40% and 69% decreased expression of Mct8 and Lat1, respectively (Fig. 6F) .
The effect of Sbp2 deficiency on selenoproteins
The mRNA expression of several selenoproteins was measured in liver (Fig. 7A) and cerebrum (Fig. 7B) . Gpx activities (Fig. 8A) and protein levels (Fig. 8B) were Five to eight mice were studied in each group. *P , 0.05; **P , 0.01; ***P , 0.001. measured in serum, liver, and cerebrum. In agreement with the previously noted selenoprotein hierarchy, the expression of some selenoproteins was more affected, whereas others were spared. For example, in Sbp2 iCKO compared with Wt mice, Gpx1, a stress selenoprotein, was significantly reduced by 75% and 51% in liver and cerebrum, respectively, whereas Txnrd1, a housekeeping selenoprotein, was preserved in both liver and cerebrum, as it is essential for survival. In addition, in Sbp2 iCKO mice compared with Wt mice, Gpx activities were significantly decreased by 52%, 82%, and 21% in serum, liver, and cerebrum, respectively (Fig. 8A) . This was also confirmed at the protein level: in Sbp2-deficient mice compared with Wt, serum Gpx3 protein was significantly decreased by 89% (Fig. 8B) , whereas Gpx1, a major Gpx protein in liver and cerebrum, was also significantly Figure 7 . The effect of Sbp2 deficiency on selenoprotein mRNA. (A) Liver and (B) cerebrum in males and females. The genes assessed in both liver and cerebrum are indicated in boldface. Five to eight mice were studied in each group. *P , 0.05; **P , 0.01; ***P , 0.001.
decreased by 91% and 34% in liver and cerebrum, respectively (Fig. 8B) . These data indicate that, in addition to the deiodinases, other selenoproteins are also affected, and a global partial Sbp2 deficiency was achieved in this mouse model.
Discussion
SBP2 is an essential factor required for the synthesis of the 25 known selenoproteins in humans. Partial SBP2 deficiency manifests a complex syndrome with multiorgan involvement reflecting broad deficiency in selenoproteins (1-5). All patients with SBP2 deficiency identified to date manifest a characteristic thyroid phenotype with high serum T4 and rT3, low T3, and elevated TSH, a phenotype that has not been seen in other inherited or acquired defects of thyroid function. These TFTs, after establishing their chronicity, are now used to identify new patients with SBP2 defects. TH is metabolized by the three iodothyronine deiodinase selenoenzymes, and the observed TFT pattern is indicative of TH metabolism defects. Thus, it has been proposed that decrease in the deiodinases activities is responsible for the phenotype (6). However, direct evidence for reduced enzymatic activity in SBP2-deficient patients was obtained only for one of the deiodinases, D2, in human skin fibroblasts (1). The exact mechanisms of the TFTs abnormalities observed in SBP2-deficient patients remain to be elucidated. As serum TFTs are the readout for the function of the thyroid axis with contributions from peripheral TH metabolism, the study of Sbp2 deficiency in an animal model was needed to investigate the tissue-specific TH status and how the interplay of the three deiodinases in different tissues contribute to the thyroid phenotype. Of note, mice lacking Sbp2 die in utero, and previous tissue-specific Sbp2-deficient mouse models have not been reported to manifest a thyroid phenotype (7, 8) .
Therefore, our goal was to generate a mouse model with partial Sbp2 deficiency with global distribution to be induced later in life to bypass the embryonic lethality. A ubiquitously expressed CreER/tamoxifen-inducible system was used, and exon 14 was targeted for deletion. Of note, in the Sbp2 iCKO mice, only one allele is floxed and thus inducible by tamoxifen injection, whereas the other allele is already constitutively null. The knockdown efficiency demonstrated at the gDNA, mRNA, and protein levels is as expected for this design, and thus, in this mouse model, partial global Sbp2 deficiency was achieved. In terms of timing of the tamoxifen induction, our goal was to provide tamoxifen postnatally at the earliest time that is compatible with survival. Injection several days after weaning (;P25) resulted in severe failure to thrive and lethality by 3 weeks after injection in the majority of the Sbp2 iCKO mice. This indicates an important role for selenoproteins in the first month of postnatal life. For the studies reported in this paper, tamoxifen was injected in the fifth week of life, between P28 and P35, and mice were analyzed 4 weeks after injection. Additional experimental paradigms with tamoxifen induction later than P35 and study of the mice several months after induction can be tested in future studies. The decreased body weight observed by 2 weeks after tamoxifen injection and maintained through the end point of these studies indicates a failure-to-thrive phenotype. This could be multifactorial: either a direct effect of Sbp2 deficiency on cellular metabolism or the consequences of the myopathy and/or impaired coordination associated with this defect in humans and the potential impact on feeding behavior and access to nutrition. These aspects will be further investigated in metabolic studies and with various dietary challenges.
In addition, a phenotype of infertility was observed in both male and female mice. This is of interest, as, in patients with SBP2 defects, infertility was reported only in males. The status of fertility in female patients with SBP2 deficiency is not known, as none of the reported females have attained the reproductive age. This phenotype in females Sbp2-deficient mice will need further investigation.
Importantly, Sbp2 iCKO mice manifest similar TFT abnormalities as those observed in SBP2-deficient humans: they have higher TSH, higher T4, similar T3, and higher rT3 compared with Wt mice. With the exception of serum T3 levels, which are low in SBP2-deficient patients, these TFTs replicate the pathognomonic thyroid phenotype of SBP2 deficiency and thus validate the utility of this mouse model for understanding the pathophysiology of the thyroid phenotype in SBP2 deficiency. It is notable that there are some differences in absolute TFTs levels when comparing males and females of both genotypes, illustrating differences in the set point and regulation of the thyroid axis between sexes.
Several aspects might account for the difference in serum T3 between Sbp2-deficient mice and patients with SBP2 defects: (1) species differences in contribution of T3 from thyroid gland vs peripheral conversion of T4 to serum T3. In humans, only ;20% of plasma T3 comes from thyroidal secretion, as opposed to ;40% in rodents (6) . (2) In addition, it is known that human skeletal muscle has relatively higher D2 activity than that of mice (6) . As skeletal muscle represents a bigger proportion of the whole body in human than in mouse, this relatively more profound D2 deficiency in human might contribute to the lower serum T3 concentration observed in SBP2-deficient patients. (3) Mouse models of Dio1KO, Dio2KO, double Dio1/Dio2, and triple Dio1/Dio2/Dio3 combined KO also show similar T3 levels compared with Wt controls, indicating that deiodinase deficiencies in these mice are not sufficient to alter circulating T3 levels. Of note, the triple Dio1/Dio2/Dio3 combined KO and the Sbp2-deficient mice are not completely comparable in terms of the timing and degree of deficiency in the deiodinases, as in the former, the defects are already present during embryonic development and complete, whereas in the Sbp2-deficient mice, the defect is induced later in development, and the deficiency in both Sbp2 and the deiodinases is partial.
Concerning the underlying mechanisms for the observed thyroid phenotype, the current work provides several advances: (1) the decreased D2 activity at the central levels results in elevated TSH, a marker of pituitary resistance to TH. The increase of the T4 resistance index by 5.3-fold in males and 12.4-fold in female Sbp2 iCKO relative to the respective Wt controls reflect this central resistance to TH. (2) The decrease in both 5 0 and 5 deiodination as well as the increase in serum TSH contribute to the elevated serum T4. (3) The reduced D1 enzymatic activity in tissues, such as liver, results in decreased degradation of rT3 and elevated serum rT3. It is possible that other tissues known to normally express high levels of D1 might also contribute to this effect. As Dio3 expression is decreased, its enzymatic activity is also expected to be decreased (17, 18) . Its effect is expected to be restricted to tissues expressing Dio3 and would result in decrease conversion of T4 to rT3 and in decreased local degradation of T3. The contribution of the thyroid gland to the observed TFT phenotype and that of other peripheral tissues will be further investigated.
The liver T4 and T3 content reflected the circulating high T4 and normal T3 levels. However, the ratio of liver T3 content to serum T3 content in individual mice was significantly lower in the Sbp2 iCKO mice compared with Wt, indicating decreased local generation of T3. When assessing TH-responsive genes, the overall TH status of the liver is euthyroid, indicating that liver is less dependent on local T3 generation by D1 and could be compensated by circulating T3 supply. Liver D1 enzymatic activity was decreased in Sbp2 iCKO compared with Wt mice primarily due to the profound decrease in Dio1 mRNA. It is important to note that Dio1 is one of the selenoproteins for which mRNA level is greatly diminished by the impaired recoding of the UGA codon due to Sbp2 deficiency (19) . Its UGA is located .50 nucleotides upstream of the exon junction, and Dio1 mRNA is subject to nonsense-mediated decay (7) .
In contrast to liver, the T3 content in cerebrum was significantly lower in Sbp2 iCKO mice, indicating local hypothyroidism, as reflected by the low expression of the TH-responsive gene Hr in these mice. This low T3 content is in part due to the low D2 enzymatic activity in setting of the decreased selenoprotein synthesis due to Sbp2 deficiency. However, cerebrum T4 content in Sbp2 iCKO mice was similar to that of Wt littermates, and it did not parallel the high circulating T4 levels. As Dio3 mRNA was decreased, both in the setting of decreased selenoprotein synthesis due to Sbp2 deficiency and as a TH positively regulated gene in setting of local low T3 content, it is less likely that the low T4 content relative to the circulating levels in Sbp2 iCKO cerebrum is due to metabolization of the local T4 to a compound other than T3, such as 5 deiodination to rT3. Another possibility considered was that the blood-brain barrier could affect T4 availability in cerebrum. In support of this hypothesis, the expression of TH transmembrane transporters Mct8, Oatp1c1, and/or Lat1 was found to be decreased in males and females, respectively. The underlying mechanisms for this finding are unknown, and further treatments with exogenous L-T4 and L-T3 are needed. The finding of low T3 content in brains of Sbp2 iCKO mice raises the possibility that individuals with SBP2 defects might also have a degree of brain hypothyroidism.
As Sbp2 is essential for selenoprotein synthesis, we tested the expression of several selenoproteins in liver and cerebrum tissues. A distinct hierarchy is known to exist in the synthesis of selenoproteins allowing for a differential preservation of some selenoproteins in the presence of unfavorable conditions for their synthesis. Selenoproteins with a housekeeping role over stress selenoproteins and the mRNA expression of selective selenoproteins such as Gpx1, Sepw1, and Selh were impaired, whereas the housekeeping Txnrd1 was spared in Sbp2 iCKO mice. Gpx3 activity in serum and Gpx1 activities in liver and brain were significantly decreased. These results confirm a global deficiency in selenoprotein synthesis in Sbp2 iCKO mice. Of note, Sepp1 mRNA expression was significantly decreased in liver, but it was preserved in cerebrum in Sbp2 iCKO mice. Although SePP1 is mainly produced in liver and secreted into blood stream and functions as an Se supplier to peripheral tissues, locally expressed SePP1 in brain is reported to be important to maintain brain Se content (20, 21) . Therefore, it is possible that cerebrum-specific posttranscriptional compensatory mechanisms maintain Sepp1 expression in Sbp-deficient mice. In fact, the decreased expression of selenoproteins in the brain was more attenuated than in the liver, indicating that selenoproteins were more preserved in the brain. This could be due in part to the tissuespecific hierarchy of selenoproteins, with the brain being preferentially preserved. How this tissue-specific allocation of selenoprotein synthesis resources is coordinated in Sbp2 iCKO mice remains to be determined.
We report the generation of a mouse model of Sbp2 deficiency that replicates global deficiency in selenoprotein synthesis, the characteristic serum thyroid tests, and other phenotypes reported in patients with SBP2 deficiency. This in vivo model represents an important tool to advance our understanding of the role of SBP2 in TH homeostasis and to investigate selenoprotein biology relevant to multiple physiological pathways. Further investigations of this mouse model regarding the other phenotypes associated with SBP2 deficiency in humans will provide important insights relevant to human health.
